Article
Pharmacology & Pharmacy
Xiao Liu, Lili Zhang, Yueying Yang, Weiwei Yin, Yunhu Liu, Chunyi Luo, Ruizhe Zhang, Zhiguo Long, Yanyan Jiang, Bing Wang
Summary: Arsenic trioxide (ATO) has been clinically used as a reliable and effective frontline drug for the treatment of acute promyelocytic leukemia (APL). However, its administration regimen is limited due to fast clearance, short therapeutic window, and toxicity. This study developed transferrin-modified liposomes encapsulating AsIII to improve its therapeutic efficacy. The AsIII-loaded liposomes exhibited acid-sensitive release and specifically targeted APL cells, leading to apoptosis and cell differentiation. Combining transferrin-modified retinoic acid liposomes further enhanced the tumor inhibition effect. The results suggest that transferrin-modified AsIII liposomes could be a novel clinical strategy for APL treatment with reduced systemic toxicity and improved efficacy.
ASIAN JOURNAL OF PHARMACEUTICAL SCIENCES
(2023)
Article
Pediatrics
Jong Hyeon Lee, Jong Ho Lee, Jae Min Lee
Summary: While ATRA is effective in treating APL, it may lead to side effects such as hearing loss. This case demonstrates that reducing the dose of ATRA and administering dexamethasone can successfully reverse ATRA-associated hearing loss. Conducting a randomized clinical trial using dexamethasone in combination with ATRA is recommended to prevent hearing loss caused by ATRA.
Review
Chemistry, Medicinal
Antonia Goncalves, Fernando Rocha, Berta N. Estevinho
Summary: Acute promyelocytic leukemia (APL) is a type of leukemia characterized by genetic abnormalities and the accumulation of abnormal promyelocytes. All-trans retinoic acid (all-trans RA) has dramatically improved the treatment of APL by promoting the differentiation of leukemic cells. Encapsulation technology using microparticle formulations obtained by spray-drying is being explored as an innovative strategy to improve the oral administration of all-trans RA. The goal is to develop a controlled delivery system that can provide a slow release of the drug in the intestines.
Review
Chemistry, Medicinal
Chengyuan Liang, Guaiping Qiao, Yuzhi Liu, Lei Tian, Nan Hui, Juan Li, Yuling Ma, Han Li, Qianqian Zhao, Wenqiang Cao, Hong Liu, Xiaodong Ren
Summary: All-trans-retinoic acid (ATRA) is effective in preventing cancer and treating skin diseases and acute promyelocytic leukaemia (APL) by regulating differentiation-related gene transcription and autophagy through inhibiting mTOR. A total of 68 ATRA analogues show promising antitumour therapeutic potential for further development and research.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
(2021)
Article
Chemistry, Medicinal
Laia Josa-Cullere, Katrina S. Madden, Thomas J. Cogswell, Thomas R. Jackson, Tom S. Carter, Douzi Zhang, Graham Trevitt, Stephen G. Davies, Paresh Vyas, Graham M. Wynne, Thomas A. Milne, Angela J. Russell
Summary: A novel compound, OXS007417, identified through a phenotypic high-throughput screen, shows promise in decreasing tumor volume in acute myeloid leukemia.
JOURNAL OF MEDICINAL CHEMISTRY
(2021)
Article
Oncology
Francesco Autore, Patrizia Chiusolo, Federica Sora, Sabrina Giammarco, Luca Laurenti, Idanna Innocenti, Elisabetta Metafuni, Nicola Piccirillo, Livio Pagano, Simona Sica
Summary: Acute promyelocytic leukemia is a variant of acute myeloid leukemia characterized by t(15;17) and PML/RAR alfa fusion gene. Treatment with a combination of all-trans retinoic acid and arsenic trioxide has shown high efficacy and tolerability, providing an alternative to chemotherapy for selected patients.
FRONTIERS IN ONCOLOGY
(2021)
Article
Oncology
Li Chen, Hongming Zhu, Yongmei Zhu, Wen Jin, Fangyi Dong, Jianfeng Li, Jiong Hu, Qiusheng Chen, Kankan Wang, Junmin Li
Summary: This study reported a rare case of BCOR-RARA variant APL and suggested that allo-HSCT after ATRA combined with chemotherapy is the optimal choice for vAPL patients with a high risk of relapse.
FRONTIERS IN ONCOLOGY
(2022)
Article
Hematology
Nithya Balasundaram, Saravanan Ganesan, Ezhilarasi Chendamarai, Hamenth Kumar Palani, Arvind Venkatraman, Ansu Abu Alex, Sachin David, Swathy Palani Kumar, Nair Reeshma Radhakrishnan, Mohammed Yasar, Sanjeev Krishna, Anu Korula, Uday Kulkarni, Nancy Beryl Janet, Poonkuzhali Balasubramanian, Vikram Mathews
Summary: This study investigates the resistance mechanisms of acute promyelocytic leukemia (APL) to arsenic trioxide (ATO) treatment. The researchers generated ATO-resistant cell lines and found significant differences in immunophenotype, drug transporter expression, anti-apoptotic protein dependence, and PML-RARA mutation compared to sensitive cell lines. Gene expression profiling revealed dysregulation of metabolic pathways in ATO-resistant APL cell lines.
Article
Immunology
Dongbei Li, Haijun Li, Cheng Cheng, Gangping Li, Fangfang Yuan, Ruihua Mi, Xiaojiao Wang, Ding Li, Ruihua Fan, Xudong Wei
Summary: The combination therapy of all-trans retinoic acid (ATRA) and ABT-199 shows a synergistic antileukemic effect by inducing apoptosis and cell cycle arrest in acute myeloid leukemia (AML) cells. In vivo, this combination therapy prolongs the survival of AML xenograft mice. The study provides a potential treatment strategy and theoretical support for overcoming the clinical ABT-199 resistance problem in AML patients.
INTERNATIONAL IMMUNOPHARMACOLOGY
(2022)
Article
Medicine, General & Internal
Xiaowei Shi, Shuangyue Li, Shanhao Tang, Ying Lu
Summary: Acute promyelocytic leukemia is a special subtype of acute myeloid leukemia with a high incidence of early death and complications. A new treatment strategy using oral all-trans retinoic acid combined with the realgar-indigo naturalis formula has shown effectiveness in patients with this condition.
Review
Biochemistry & Molecular Biology
Carmelo Gurnari, Maria Teresa Voso, Katia Girardi, Angela Mastronuzzi, Luisa Strocchio
Summary: The combination therapy of ATRA and ATO has shown high survival rates in pediatric APL patients, while also reducing the occurrence of long-term sequelae. However, there are also special issues and challenges such as pseudotumor cerebri and early death during induction in the treatment process.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Article
Cell Biology
Dong-Hwan Kim, Joonbum Lee, Yeunsu Suh, Jae-Kyun Ko, Kichoon Lee
Summary: This study found that all-trans-retinoic acid (atRA) can induce the transdifferentiation of myoblasts into adipocytes by increasing the expression of Ppar gamma. This discovery provides a new nutrient for enhancing marbling in poultry.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY
(2022)
Review
Medicine, General & Internal
Mengyu Xiao, Ling Qin, Xiaona Niu, Pan Zhou, Junwei Niu, Shengjie Wei, Dan Li, Liurui Dou, Wanjun Zhang, Lei Zhang, Kai Sun, Yanliang Bai
Summary: This case report highlighted the rarity of acute promyelocytic leukemia with myelofibrosis and emphasized the importance of evaluating and intervening in cases of myelofibrosis.
Article
Multidisciplinary Sciences
Li Chen, Hong-Ming Zhu, Yan Li, Qi-Fa Liu, Yu Hu, Jian-Feng Zhou, Jie Jin, Jian-Da Hu, Ting Liu, De-Pei Wu, Jie-Ping Chen, Yong-Rong Lai, Jian-Xiang Wang, Juan Li, Jian-Yong Li, Xin Du, Xin Wang, Ming-Zhen Yang, Jin-Song Yan, Gui-Fang Ouyang, Li Liu, Ming Hou, Xiao-Jun Huang, Xiao-Jing Yan, Dan Xu, Wei-Ming Li, Deng-Ju Li, Yin-Jun Lou, Zheng-Jun Wu, Ting Niu, Ying Wang, Xiao-Yang Li, Jian-Hua You, Hui-Jin Zhao, Yu Chen, Yang Shen, Qiu-Sheng Chen, Jian Li, Bing-Shun Wang, Wei-Li Zhao, Jian-Qing Mi, Kan-Kan Wang, Jiong Hu, Zhu Chen, Sai-Juan Chen, Jun-Min Li
Summary: This study found that the combination of all-trans retinoic acid and arsenic trioxide in treating acute promyelocytic leukemia during consolidation therapy is not inferior to traditional chemotherapy regimens and shows better outcomes in reducing relapse and toxicity.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
(2021)
Review
Oncology
Jaime Sanz, Pau Montesinos, Miguel A. Sanz
Summary: The historical evolution of hematopoietic stem cell transplantation (HSCT) in acute promyelocytic leukemia (APL) has shifted from widespread use to rejection in modern treatments, with ATO-based regimens now considered the first option for relapsed cases. The use of HSCT depends on variables such as pre-transplant molecular status and age, and recent studies have questioned the superiority of HSCT over other consolidation options, suggesting the need for further research.
FRONTIERS IN ONCOLOGY
(2021)